Updated: 24th August 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder and CEO)
Why UK Medical Device Regulations Matter
Medical devices placed on the UK market are subject to a regulatory framework designed to ensure that products are safe, perform as intended and continue to meet applicable requirements throughout their lifecycle.
Since the UK’s departure from the European Union, manufacturers have also had to navigate important differences between the regulatory requirements applying in Great Britain — England, Scotland and Wales — and those applying in Northern Ireland.
For the Great Britain market, medical devices are primarily regulated under the UK Medical Devices Regulations 2002 (UK MDR 2002), as amended, with the Medicines and Healthcare products Regulatory Agency (MHRA) acting as the responsible regulatory authority.
Manufacturers may need to consider requirements including:
- Medical device classification.
- UKCA or recognised CE marking routes.
- MHRA device registration.
- Appointment of a UK Responsible Person (UKRP) for manufacturers based outside the UK.
- Technical documentation and clinical evidence.
- Quality and risk management.
- Post-market surveillance and vigilance.
The UK regulatory landscape is also continuing to evolve. New post-market surveillance requirements have been introduced, while the government and MHRA continue to develop the future regulatory framework for medical devices and routes for recognising international regulatory approvals.
For manufacturers developing a new medical device, entering the Great Britain market or maintaining an existing product portfolio, understanding both the current requirements and the direction of future reform is therefore essential.
This guide explains the key requirements for regulating medical devices in the UK, from classification and market access through to MHRA registration, UK Responsible Person requirements, post-market surveillance and ongoing regulatory compliance.
What Are the UK Medical Device Regulations?
Medical devices placed on the Great Britain market are primarily regulated under the Medical Devices Regulations 2002 (SI 2002 No. 618), commonly referred to as the UK MDR 2002.
The UK MDR 2002, as amended, establishes the legal framework governing medical devices in England, Scotland and Wales and sets requirements covering areas such as:
- Medical device classification.
- Conformity assessment.
- UKCA marking.
- MHRA device registration.
- Technical documentation.
- Clinical evidence.
- Quality management.
- Post-market surveillance.
- Vigilance and incident reporting.
- Ongoing regulatory compliance.
The current UKCA framework remains based substantially on requirements derived from the former European medical device directives, including the Medical Devices Directive (MDD), Active Implantable Medical Devices Directive (AIMDD) and In Vitro Diagnostic Medical Devices Directive (IVDD).
However, the regulatory framework in Great Britain is continuing to evolve through amendments to the UK MDR 2002 and the development of a future regulatory regime for medical devices.
UK MDR and EU MDR Are Not the Same
Manufacturers should not treat the UK MDR 2002 and the EU Medical Device Regulation (EU MDR 2017/745) as interchangeable regulatory frameworks.
The EU MDR applies within the European Union and, under separate arrangements, is also relevant to medical devices placed on the Northern Ireland market. Great Britain operates under the UK MDR 2002.
However, valid CE-marked medical devices can currently continue to be placed on the Great Britain market under transitional recognition arrangements. The applicable deadline depends on the type of device and the European legislation under which it has been certified.
This means manufacturers entering the UK market need to consider both the regulatory route used to demonstrate product conformity and the additional UK-specific requirements that may apply, including MHRA registration and appointment of a UK Responsible Person for manufacturers based outside the UK.
As the UK regulatory framework continues to develop, manufacturers should ensure that their regulatory strategy reflects both the requirements currently in force and upcoming changes introduced by the MHRA and UK Government.
The Role of the Medicines and Healthcare Products Regulatory Agency (MHRA)
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating the medical devices market in the United Kingdom and acts as the market surveillance authority for medical devices.
For devices placed on the Great Britain market, the MHRA oversees compliance with the UK Medical Devices Regulations 2002 (UK MDR 2002), as amended.
Its responsibilities include:
- Maintaining the UK medical device registration system.
- Overseeing medical device registration requirements.
- Designating and monitoring UK Approved Bodies.
- Publishing regulatory guidance for manufacturers and other economic operators.
- Monitoring post-market surveillance and vigilance activities.
- Investigating safety concerns and incidents involving medical devices.
- Taking regulatory action where devices fail to meet applicable requirements.
- Supporting the development and implementation of future UK medical device regulations.
The MHRA does not routinely assess or approve every medical device before it is placed on the market. Depending on the device classification and conformity assessment route, assessment may instead be undertaken by a UK Approved Body, or the manufacturer may be permitted to self-declare conformity.
Once a medical device is on the UK market, the MHRA has an important role in market surveillance. Manufacturers must report certain incidents and take appropriate corrective or preventive action where safety issues are identified.
The regulatory framework is also continuing to evolve. Manufacturers should therefore monitor MHRA guidance and legislative developments to ensure their regulatory strategy remains aligned with both current requirements and forthcoming changes.
Medical Device Classification in the UK
Correctly classifying a medical device is one of the first steps towards regulatory compliance in Great Britain. Classification determines the applicable conformity assessment route, the level of regulatory scrutiny and whether involvement from a UK Approved Body is required.
Under the UK MDR 2002, general medical devices are divided into four main risk classes:
- Class I – generally considered low risk.
- Class IIa – lower-medium risk.
- Class IIb – higher-medium risk.
- Class III – the highest-risk devices.
Certain Class I devices have additional characteristics, including devices supplied sterile, devices with a measuring function and reusable surgical instruments. These characteristics can affect the conformity assessment requirements that apply.
Classification is not determined simply by the type of product. Manufacturers must apply the relevant classification rules and consider factors including:
- The device’s intended purpose.
- Duration of use.
- Whether it is invasive or surgically invasive.
- Whether it is implantable.
- Whether it is an active device.
- The part of the body with which it interacts.
- Whether it incorporates certain substances or medicinal products.
The higher the risk classification, the greater the regulatory controls generally become. While many Class I devices can be self-declared for UKCA marking, higher-risk devices require conformity assessment by a UK Approved Body.
Correct classification is therefore critical. An incorrectly classified device may follow the wrong conformity assessment route, resulting in inadequate technical documentation, inappropriate certification or delays in placing the device on the Great Britain market.
Unsure How Your Medical Device Is Classified in the UK?
Correct classification is a critical first step in determining the regulatory route for a medical device in Great Britain. For a detailed explanation of Class I, IIa, IIb and III devices, the UK classification rules, practical examples and how classification affects conformity assessment, read our Medical Device Classification in the UK guide.
UKCA Marking for Medical Devices
The UKCA (UK Conformity Assessed) mark is the conformity marking available for medical devices placed on the Great Britain market under the UK Medical Devices Regulations 2002 (UK MDR 2002).
To apply the UKCA mark, manufacturers must demonstrate that their device meets the applicable requirements of the UK MDR 2002 and follow the appropriate conformity assessment procedure.
The route depends largely on the classification and characteristics of the device.
For many Class I medical devices, the manufacturer can self-declare conformity. However, involvement of a UK Approved Body is generally required for higher-risk devices and for certain Class I devices, such as those supplied sterile or with a measuring function.
Where Approved Body involvement is required, the organisation assesses the relevant aspects of the manufacturer’s conformity with the UK regulatory requirements before the UKCA mark can be applied.
Do Medical Devices Need UKCA Marking to Be Sold in Great Britain?
Not necessarily.
Although UKCA is the UK’s domestic conformity assessment marking for medical devices, qualifying CE-marked medical devices can currently continue to be placed on the Great Britain market under transitional recognition arrangements.
The period for which a CE-marked device can continue to be placed on the GB market depends on the legislation and certification route applying to the device.
Under the current arrangements:
- Certain devices compliant with the former EU medical device directives may continue to be placed on the Great Britain market until the sooner of certificate expiry or 30 June 2028, subject to the applicable conditions.
- Medical devices compliant with the EU Medical Device Regulation (EU MDR) and in vitro diagnostic medical devices compliant with the EU In Vitro Diagnostic Medical Devices Regulation (EU IVDR) may generally continue to be placed on the Great Britain market until 30 June 2030, subject to the applicable requirements.
Manufacturers should therefore assess their existing certification, device type and intended market before deciding whether to pursue UKCA marking or continue using an eligible CE-marking route.
UKCA and CE Marking Are Different Regulatory Routes
A UKCA mark and a CE mark should not be treated as equivalent certifications.
UKCA marking demonstrates conformity with the applicable Great Britain regulatory requirements, while CE marking demonstrates conformity with the applicable European regulatory framework.
Manufacturers supplying devices across both Great Britain and the European Union may therefore need to maintain a regulatory strategy that considers both markets.
Regardless of whether an eligible device enters Great Britain using UKCA or recognised CE marking, additional UK requirements may still apply, including MHRA registration and appointment of a UK Responsible Person where the manufacturer is based outside the UK.
Need to Comply with Both the UK MDR and EU MDR?
Manufacturers supplying medical devices in both Great Britain and the European Union need to understand the differences between the two regulatory frameworks. For a practical comparison of UKCA and CE marking, classification, conformity assessment, technical documentation, economic operators and market access requirements, read our EU MDR and UK MDR Practical Compliance Guide.
UK Approved Bodies
Many medical devices require independent conformity assessment before the manufacturer can apply the UKCA mark.
This assessment is carried out by a UK Approved Body — an organisation designated by the Medicines and Healthcare products Regulatory Agency (MHRA) to assess conformity with the applicable requirements of the UK Medical Devices Regulations 2002 (UK MDR 2002).
Depending on the device classification and conformity assessment route, a UK Approved Body may assess areas including:
- Technical Documentation.
- Clinical evidence.
- Quality Management Systems.
- Risk management documentation.
- Manufacturing and quality processes.
- Post-market surveillance procedures.
- Compliance with the applicable requirements of the UK MDR 2002.
Following successful conformity assessment, the Approved Body can issue the relevant certification required to support UKCA marking.
UK Approved Bodies and EU Notified Bodies
UK Approved Bodies and EU Notified Bodies perform similar conformity assessment functions, but they operate under different regulatory frameworks.
A UK Approved Body is designated to perform conformity assessment for UKCA marking in Great Britain. It cannot issue CE certification under the EU MDR or EU IVDR.
For CE marking under European medical device legislation, manufacturers requiring third-party conformity assessment must use an appropriately designated EU Notified Body.
Manufacturers selling medical devices in both Great Britain and the European Union should therefore consider whether their regulatory strategy requires certification for one or both markets.
When selecting a UK Approved Body, manufacturers should also confirm that the organisation’s designation covers the relevant device type and conformity assessment activities required for their product.
The UK Responsible Person (UKRP)
Manufacturers based outside the United Kingdom that wish to place medical devices on the Great Britain market must appoint a UK Responsible Person (UKRP).
The UKRP is established in the UK and acts on behalf of the overseas manufacturer in relation to specified regulatory responsibilities under the UK Medical Devices Regulations 2002 (UK MDR 2002).
One of the UKRP’s most important responsibilities is ensuring that the manufacturer’s medical devices are registered with the Medicines and Healthcare products Regulatory Agency (MHRA) before being placed on the Great Britain market.
Other responsibilities include:
- Ensuring that the required Declaration of Conformity and Technical Documentation have been prepared.
- Checking that the appropriate conformity assessment procedure has been completed where required.
- Keeping relevant regulatory documentation available for inspection by the MHRA.
- Providing information and documentation to the MHRA when requested.
- Cooperating with the MHRA on actions required to eliminate or mitigate risks associated with a device.
- Acting as an important regulatory contact between the manufacturer and the MHRA.
The manufacturer must formally designate the UK Responsible Person and provide written evidence that the UKRP has authority to act on its behalf.
Who Needs a UK Responsible Person?
The requirement applies to manufacturers based outside the UK that place medical devices on the Great Britain market. This includes manufacturers based within the European Union.
A UK Responsible Person is therefore an important consideration for overseas manufacturers entering or continuing to supply the GB medical device market.
The UKRP requirement is separate from the role of an importer or distributor. Manufacturers should ensure that the organisation they appoint understands its regulatory responsibilities and has the appropriate expertise and processes to support ongoing compliance.
Although the UKRP performs specified regulatory duties on behalf of an overseas manufacturer, appointing a UKRP does not remove the manufacturer’s responsibility for ensuring that its devices comply with the applicable regulatory requirements.
Do You Need a UK Responsible Person?
If your organisation is based outside the UK and places medical devices on the Great Britain market, you will need to understand the UK Responsible Person (UKRP) requirements. Our dedicated guide explains who needs a UKRP, their regulatory responsibilities, MHRA registration requirements and how the UKRP supports ongoing compliance. Read our complete guide to UK Responsible Person requirements for medical devices.
MHRA Medical Device Registration
All medical devices must be registered with the Medicines and Healthcare products Regulatory Agency (MHRA) before they are placed on the Great Britain market.
This requirement applies to:
- Class I, IIa, IIb and III medical devices.
- In vitro diagnostic medical devices (IVDs).
- Custom-made medical devices.
- Systems and procedure packs.
Registration provides the MHRA with information about the manufacturer and the medical devices being supplied in Great Britain and forms an important part of the UK’s market surveillance framework.
Who Registers a Medical Device with the MHRA?
For manufacturers established in the UK, the manufacturer is responsible for registering its devices with the MHRA.
Where the manufacturer is based outside the UK, it must appoint a UK Responsible Person (UKRP). The UKRP then undertakes the MHRA registration of the manufacturer’s devices on its behalf.
Registration is completed through the MHRA’s Device Online Registration System (DORS).
Manufacturers and UK Responsible Persons must ensure that the information held by the MHRA remains accurate and up to date and make appropriate changes when registered information changes.
What Information Is Required for MHRA Registration?
The information required will depend on the device and manufacturer but can include:
- Manufacturer details.
- UK Responsible Person details, where applicable.
- Applicable medical device legislation.
- Device classification.
- Global Medical Device Nomenclature (GMDN) information.
- Device name and model information.
- Conformity assessment and certification details.
- UKCA or CE marking information, as applicable.
Manufacturers should ensure that the appropriate conformity assessment requirements have been addressed before submitting their registration.
Importantly, MHRA registration does not represent regulatory approval, certification or endorsement of a medical device. Manufacturers remain responsible for demonstrating that their devices comply with the applicable regulatory requirements.
MHRA Medical Device Registration Fees
From 1 April 2026, the MHRA introduced a new annual fee structure for medical device registrations.
For the 2026–2027 charging period, manufacturers are charged £300 per applicable Level 2 Global Medical Device Nomenclature (GMDN) category, or Level 1 category where no Level 2 category exists.
The fee structure is intended to contribute towards the MHRA’s strengthened post-market surveillance activities and regulatory oversight of medical devices.
Proposed Increase from April 2027
In August 2026, the MHRA launched a public consultation proposing changes to its statutory fees from 1 April 2027.
Under the proposal, the annual medical device registration fee would increase from £300 to £511 per chargeable GMDN Level 2 category.
The MHRA has stated that the proposed fee would continue the phased introduction of charges associated with strengthened medical device post-market surveillance, rather than moving immediately to full cost recovery.
The proposed £511 fee is currently subject to public consultation and should not therefore be treated as a confirmed future charge. The consultation is scheduled to close on 25 September 2026.
Manufacturers and UK Responsible Persons should monitor the outcome of the consultation and review their registered GMDN categories to understand the potential impact of future registration fees.
Technical Documentation Requirements
Medical devices placed on the Great Britain market must be supported by appropriate Technical Documentation demonstrating conformity with the applicable requirements of the UK Medical Devices Regulations 2002 (UK MDR 2002).
Technical Documentation provides the evidence that a device has been appropriately designed, manufactured, verified and validated and that its safety and performance have been adequately demonstrated.
The exact documentation required will depend on the type of device, its classification, intended purpose and applicable conformity assessment route. However, a medical device Technical File will typically include:
- Device description, specification and intended purpose.
- Design and manufacturing information.
- Evidence demonstrating conformity with the applicable Essential Requirements.
- Risk Management documentation.
- Clinical Evaluation and supporting clinical evidence.
- Biological Evaluation, where applicable.
- Verification and validation evidence.
- Software validation documentation, where applicable.
- Electrical safety and performance testing, where applicable.
- Usability Engineering documentation.
- Labelling and Instructions for Use (IFU).
- Post-Market Surveillance documentation.
- Relevant conformity assessment certificates, where applicable.
- Declaration of Conformity.
Demonstrating Compliance with the Essential Requirements
Manufacturers must identify which Essential Requirements of the UK MDR 2002 apply to their device and provide evidence demonstrating how those requirements have been satisfied.
Relevant designated standards can provide an important means of demonstrating conformity with particular requirements. Depending on the device, these may include standards relating to areas such as quality management, risk management, biological safety, electrical safety, software lifecycle processes and usability engineering.
Technical Documentation should clearly connect the applicable regulatory requirements with the evidence demonstrating that those requirements have been met.
Technical Documentation Is a Lifecycle Requirement
Preparing a Technical File should not be treated as a one-off activity completed solely for initial market access.
Manufacturers must maintain appropriate documentation throughout the lifecycle of the device and update it where necessary to reflect information such as:
- Changes to the device or its intended purpose.
- New verification or validation evidence.
- Changes to applicable standards or regulatory requirements.
- Updated risk management information.
- Clinical Evaluation updates.
- Post-Market Surveillance findings.
- Corrective and Preventive Actions (CAPAs).
- Field Safety Corrective Actions (FSCAs), where applicable.
Maintaining clear, structured and current Technical Documentation helps manufacturers demonstrate continued conformity and ensures that relevant evidence can be made available to the MHRA or UK Approved Body when required.
Manufacturers requiring support with their documentation can also explore Patient Guard’s UKCA Marking Technical File services, including technical file preparation, gap assessment, review and remediation for medical devices placed on the Great Britain market.
Clinical Evidence and Clinical Evaluation
Manufacturers must have sufficient clinical evidence to demonstrate that their medical device is safe, performs as intended and has an acceptable benefit-risk profile when used for its intended purpose.
Clinical evaluation is the systematic assessment of clinical data relating to the device and forms an important part of demonstrating conformity with the applicable requirements of the UK Medical Devices Regulations 2002 (UK MDR 2002).
Clinical evidence may be obtained from sources including:
- Relevant scientific and clinical literature.
- Clinical investigations involving the device.
- Clinical experience with the device.
- Data relating to an equivalent device, where equivalence can be appropriately demonstrated.
- Post-market surveillance data.
- Post-Market Clinical Follow-up (PMCF).
The available evidence should be critically evaluated to determine whether it adequately supports the safety, performance and intended purpose of the device.
When Is a Clinical Investigation Required?
Not every medical device requires a new clinical investigation.
Where sufficient clinical evidence already exists, manufacturers may be able to demonstrate conformity using existing clinical data, relevant scientific literature or data from an equivalent device.
However, where the available evidence is insufficient to demonstrate safety and performance, a specifically designed clinical investigation may be required.
Clinical investigations are particularly important where devices introduce significant novelty, where existing evidence cannot adequately address identified clinical risks or where the safety and performance of the device cannot otherwise be sufficiently demonstrated.
For clinical investigations conducted in Great Britain, manufacturers must determine whether notification to the MHRA is required before the investigation begins.
Clinical Evaluation Continues Throughout the Device Lifecycle
Clinical evaluation should not be treated as a one-time activity undertaken only before a medical device enters the market.
Manufacturers should continue to review clinical evidence as new information becomes available through post-market surveillance, complaints, vigilance, published literature and Post-Market Clinical Follow-up activities.
New clinical information should feed back into the Clinical Evaluation, Risk Management and Post-Market Surveillance processes to support continued assessment of the device’s safety, performance and benefit-risk profile.
Need More Guidance on Medical Device Clinical Evaluation?
Clinical Evaluation is a key part of demonstrating the safety, clinical performance and benefit-risk profile of a medical device. For detailed guidance on Clinical Evaluation Plans (CEPs), Clinical Evaluation Reports (CERs), clinical evidence, literature reviews, equivalence, PMCF and ongoing lifecycle updates, read our complete guide to Medical Device Clinical Evaluation.
Quality Management Systems (ISO 13485)
An effective Quality Management System (QMS) is an important part of maintaining medical device regulatory compliance in Great Britain.
The quality management requirements that apply will depend on the device classification and conformity assessment route under the UK Medical Devices Regulations 2002 (UK MDR 2002).
ISO 13485 is the internationally recognised quality management system standard specifically developed for organisations involved in the medical device lifecycle. Although ISO 13485 certification is not universally mandatory for every medical device manufacturer, implementing a QMS aligned with the standard provides a structured framework for meeting many regulatory and quality management responsibilities.
An effective medical device QMS can support:
- Design and development controls.
- Document and record control.
- Supplier and purchasing controls.
- Manufacturing and process controls.
- Risk Management.
- Complaint handling.
- Corrective and Preventive Actions (CAPA).
- Internal auditing.
- Management review.
- Post-Market Surveillance.
- Vigilance and regulatory reporting.
- Control of product and process changes.
Quality Management Is a Lifecycle Process
A QMS should not be developed simply to achieve certification or pass an initial conformity assessment.
Manufacturers should use their quality system to continually manage regulatory compliance throughout the lifecycle of the medical device.
Information from complaints, Post-Market Surveillance, vigilance, Clinical Evaluation, Risk Management, internal audits and CAPA activities should feed back into the QMS and support continual improvement.
For manufacturers requiring involvement from a UK Approved Body, the quality management system may form an important part of the conformity assessment process, depending on the route being followed.
A well-implemented QMS therefore provides more than a set of procedures. It creates the organisational framework through which manufacturers can consistently control their devices, respond to emerging issues and demonstrate ongoing regulatory compliance.
Need to Understand ISO 13485?
ISO 13485 provides the internationally recognised framework for medical device Quality Management Systems and supports regulatory compliance throughout the device lifecycle. For detailed guidance on QMS requirements, documentation, design controls, risk management, CAPA, internal audits, certification and continual improvement, read our complete guide to ISO 13485 for medical devices.
Risk Management Throughout the Device Lifecycle
Risk management is a fundamental part of demonstrating and maintaining the safety of a medical device throughout its lifecycle.
Manufacturers should establish a systematic process for identifying hazards, estimating and evaluating associated risks, implementing appropriate risk control measures and monitoring whether those controls remain effective.
ISO 14971 provides the internationally recognised framework for applying risk management to medical devices and is a designated standard supporting the UK Medical Devices Regulations 2002 (UK MDR 2002).
An effective risk management process should include:
- Establishing a Risk Management Plan.
- Identifying known and foreseeable hazards.
- Estimating and evaluating associated risks.
- Implementing appropriate risk control measures.
- Evaluating residual risks.
- Performing benefit-risk analysis where required.
- Reviewing the overall residual risk of the device.
- Maintaining a Risk Management Report and Risk Management File.
- Reviewing production and post-production information throughout the device lifecycle.
Risk Management Does Not End at Market Access
Risk management should not be treated as a one-time exercise completed before UKCA marking or initial market access.
Once a device is placed on the Great Britain market, manufacturers must continue to evaluate information that could affect its safety, performance or benefit-risk profile.
Information generated through:
- Post-Market Surveillance.
- Complaints and customer feedback.
- Vigilance and serious incident reporting.
- Clinical Evaluation.
- Post-Market Clinical Follow-up (PMCF).
- CAPA investigations.
- Field Safety Corrective Actions.
- Published scientific and clinical literature.
should feed back into the Risk Management File where relevant.
This feedback loop enables manufacturers to identify new hazards, reassess known risks, evaluate whether existing risk controls remain effective and implement additional measures where necessary.
Risk Management should therefore operate alongside Clinical Evaluation, Post-Market Surveillance and the Quality Management System as a continuous lifecycle process rather than as a standalone regulatory document.
Need to Understand ISO 14971 Risk Management?
ISO 14971 provides the internationally recognised framework for identifying hazards, evaluating risks, implementing risk controls and monitoring device safety throughout the product lifecycle. For detailed guidance on Risk Management Plans, risk analysis, risk evaluation, benefit-risk analysis, residual risk, Risk Management Files and post-production monitoring, read our complete guide to ISO 14971 Risk Management for medical devices and IVDs.
Post-Market Surveillance and Vigilance
Post-Market Surveillance (PMS) is a fundamental part of maintaining medical device compliance after a product has been placed on the Great Britain market.
The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 strengthened the UK’s post-market requirements and introduced a new Part 4A into the UK Medical Devices Regulations 2002 (UK MDR 2002).
These requirements came into force on 16 June 2025 and apply to medical devices placed on the Great Britain market or put into service from that date, including devices using eligible CE marking and UKCA marking routes.
Manufacturers must establish a structured PMS system that enables them to proactively collect, analyse and evaluate information relating to the safety, quality and performance of their devices.
An effective PMS system should enable manufacturers to:
- Collect and analyse complaints and user feedback.
- Monitor real-world device safety and performance.
- Identify previously unknown or emerging risks.
- Detect changes in the frequency or severity of known risks.
- Review the continued acceptability of the device’s benefit-risk profile.
- Identify opportunities for preventive and corrective action.
- Update Risk Management and Clinical Evaluation documentation.
- Feed relevant information into the Quality Management System.
- Identify incidents and trends that require reporting to the MHRA.
PMS Plans, PMSRs and PSURs
Manufacturers must establish a Post-Market Surveillance Plan describing how post-market information will be proactively collected and assessed.
The reporting requirements then vary according to the type and risk classification of the device.
Under the current Great Britain requirements:
- Class I medical devices generally require a Post-Market Surveillance Report (PMSR).
- Class II and Class III medical devices require a Periodic Safety Update Report (PSUR).
- IVDs may require either a PMSR or PSUR depending on their classification.
These reports should critically evaluate the information gathered through PMS and consider whether new information affects the device’s safety, performance or benefit-risk profile.
Manufacturers must maintain the appropriate report throughout the applicable PMS period and make the most up-to-date version available to the MHRA when requested.
Medical Device Vigilance
Vigilance is closely connected with Post-Market Surveillance and covers the identification, investigation and reporting of certain incidents involving medical devices.
Manufacturers must have documented processes for determining whether an incident meets the applicable reporting criteria and for notifying the MHRA within the required regulatory timescales.
The vigilance system includes:
- Serious incident reporting.
- Investigation of reported incidents.
- Trend reporting.
- Periodic summary reporting where applicable.
- Field Safety Corrective Actions (FSCAs).
- Field Safety Notices (FSNs).
- Communication and cooperation with the MHRA.
Where a safety issue is identified, manufacturers may need to take corrective action to reduce the risk associated with devices already on the market.
Post-Market Data Must Feed Back Into Regulatory Compliance
PMS should not operate as an isolated regulatory process.
Information generated after market entry should feed back into relevant parts of the manufacturer’s compliance system, including:
- Risk Management.
- Clinical Evaluation.
- Technical Documentation.
- Quality Management.
- CAPA.
- Product design and manufacturing controls.
- Labelling and Instructions for Use.
This creates a continuous feedback loop in which real-world information is used to confirm that the device remains safe, performs as intended and continues to have an acceptable benefit-risk profile throughout its lifecycle.
Need to Understand Post-Market Surveillance Requirements?
Post-Market Surveillance is an ongoing lifecycle requirement for medical devices and IVDs, with strengthened requirements applying in Great Britain since June 2025. For detailed guidance on PMS systems, PMS Plans, PMS Reports, PSURs, vigilance, trend reporting, PMCF, PMPF and how post-market data feeds back into risk management and clinical or performance evaluation, read our complete guide to Post-Market Surveillance for medical devices and IVDs.
Common UK Medical Device Compliance Mistakes
Many regulatory problems encountered by medical device manufacturers in Great Britain can be traced back to decisions made early in the regulatory process or to compliance systems that have not been adequately maintained after market entry.
Some of the most common issues include:
Incorrect Medical Device Classification
Incorrect classification can result in a manufacturer following the wrong conformity assessment route, involving the wrong regulatory body or preparing insufficient supporting evidence.
Classification should therefore be established early and documented with a clear rationale based on the device’s intended purpose and applicable classification rules.
Assuming CE Marking Automatically Covers All UK Requirements
Eligible CE-marked devices can currently access the Great Britain market under transitional recognition arrangements, but CE marking does not remove UK-specific obligations.
Manufacturers may still need to appoint a UK Responsible Person, register their devices with the MHRA and comply with applicable Great Britain post-market surveillance and vigilance requirements.
Incomplete or Poorly Structured Technical Documentation
Technical Documentation should clearly demonstrate how the device meets the applicable requirements of the UK MDR 2002.
Common problems include missing verification or validation evidence, weak traceability between documents, outdated information and documentation that does not adequately reflect the current device design or intended purpose.
Insufficient Clinical Evidence
Clinical Evaluation should provide sufficient evidence to demonstrate the safety and performance of the device.
Manufacturers can encounter difficulties where literature searches are poorly designed, equivalence claims are inadequately justified, clinical evidence does not support the intended purpose or post-market information is not incorporated into the Clinical Evaluation.
Weak Risk Management
Risk Management should operate throughout the entire device lifecycle.
Common weaknesses include incomplete hazard identification, inadequate justification of risk controls, poor benefit-risk analysis and failure to update the Risk Management File when new information becomes available.
Failing to Appoint a UK Responsible Person
Manufacturers based outside the UK must ensure that an appropriate UK Responsible Person is appointed before placing devices on the Great Britain market.
The UKRP should be formally designated and have the authority and processes necessary to perform the regulatory responsibilities assigned to it.
Incorrect or Outdated MHRA Registration
MHRA registration information must accurately reflect the manufacturer and devices being placed on the Great Britain market.
Manufacturers and UK Responsible Persons should ensure that registration information remains current when devices, certification or other relevant regulatory information changes.
Treating Post-Market Surveillance as a Complaint-Handling Exercise
Post-Market Surveillance must be proactive.
Manufacturers should systematically collect and evaluate information from multiple post-market sources rather than relying solely on complaints or serious incidents.
PMS findings should feed back into Risk Management, Clinical Evaluation, Technical Documentation, CAPA and other relevant parts of the Quality Management System.
Failing to Maintain Compliance After Market Entry
Achieving initial market access is not the end of the regulatory process.
Manufacturers must continue to maintain Technical Documentation, monitor device safety and performance, manage changes, review regulatory developments and update their compliance systems throughout the device lifecycle.
Taking a structured lifecycle approach to UK medical device compliance can reduce regulatory delays, identify emerging issues earlier and help manufacturers maintain continued access to the Great Britain market.
The Future of UK Medical Device Regulations
The regulatory framework for medical devices in Great Britain is continuing to evolve as the UK Government and MHRA implement reforms to the UK Medical Devices Regulations 2002.
Rather than introducing an entirely new regulatory framework at once, the reforms are being implemented progressively. Manufacturers therefore need to comply with the requirements currently in force while also preparing for regulatory changes that may affect future market access.
Key areas of reform include:
- Strengthened Post-Market Surveillance requirements.
- Changes to pre-market regulatory requirements.
- Greater use of Unique Device Identification (UDI).
- Enhanced traceability requirements.
- New requirements relating to implantable medical devices.
- Development of international recognition and reliance routes.
- Changes affecting Software as a Medical Device (SaMD).
- Greater regulatory transparency and information sharing.
- Continued development of the UK’s domestic conformity assessment framework.
Post-Market Surveillance Reform
One of the most significant reforms already implemented is the strengthening of Post-Market Surveillance requirements in Great Britain.
The new requirements came into force on 16 June 2025 and introduced more detailed obligations relating to PMS systems, serious incident reporting, trend reporting, PMS Reports and Periodic Safety Update Reports.
Manufacturers should therefore ensure that their post-market systems reflect the requirements currently in force rather than waiting for the wider UK regulatory reforms to be completed.
Future Pre-Market Requirements
Further changes to the pre-market regulatory framework are being developed.
These reforms are expected to affect areas such as device identification, traceability, conformity assessment, implantable devices and the regulatory information manufacturers must maintain.
Manufacturers developing new products or planning long-term access to the Great Britain market should therefore consider future regulatory requirements as part of their regulatory strategy rather than focusing solely on the rules applying today.
International Recognition and Reliance
The UK is also developing new approaches to recognising regulatory approvals from trusted international jurisdictions.
These proposals are intended to provide additional routes to the Great Britain market for certain medical devices that have already undergone regulatory assessment in other countries, while maintaining appropriate safeguards for patient safety.
International recognition does not mean that overseas approval will automatically remove all UK regulatory obligations. Manufacturers may still need to meet UK-specific requirements relating to registration, representation, post-market surveillance and regulatory oversight.
Manufacturers Should Plan for Regulatory Change
The transition to the future UK medical device framework will continue over several stages.
Manufacturers should therefore:
- Monitor MHRA and UK Government regulatory updates.
- Assess how proposed changes could affect existing products.
- Review regulatory strategies for products currently in development.
- Maintain current Technical Documentation.
- Ensure Post-Market Surveillance systems meet requirements already in force.
- Review UKCA and CE-marking strategies.
- Consider future UDI and traceability requirements.
- Maintain appropriate regulatory resources to manage future changes.
Taking a proactive approach can help manufacturers avoid rushed remediation projects and maintain continuity of access to the Great Britain market as the regulatory framework develops.
Preparing for the Future UK Medical Device Regulations?
The UK medical device regulatory framework is undergoing significant reform, with proposed changes affecting market access, IVD classification, software and AI medical devices, international recognition, UDI, technical documentation and future UKCA compliance. For a detailed explanation of the proposed changes and what manufacturers should be preparing for, read our MHRA 2026 Regulatory Roadmap Explained.
Summary
Successfully placing and maintaining a medical device on the Great Britain market requires manufacturers to understand a range of regulatory requirements under the UK Medical Devices Regulations 2002 (UK MDR 2002).
Depending on the device and regulatory route, manufacturers may need to address:
- Medical device classification.
- UKCA or recognised CE-marking routes.
- Conformity assessment and UK Approved Body involvement.
- Appointment of a UK Responsible Person (UKRP).
- MHRA medical device registration.
- Technical Documentation.
- Clinical Evaluation and clinical evidence.
- Quality Management Systems.
- Risk Management.
- Post-Market Surveillance and vigilance.
Regulatory compliance also continues after a device reaches the market. Manufacturers must maintain their Technical Documentation, monitor real-world safety and performance, evaluate emerging risks and ensure that relevant clinical, risk management and post-market information remains up to date.
The Great Britain regulatory framework is continuing to evolve, with strengthened Post-Market Surveillance requirements already in force and further reforms being developed across areas including device identification, traceability, international recognition and future market access.
Manufacturers should therefore consider both the requirements that apply today and forthcoming regulatory developments when developing their UK market-access strategy.
A structured, lifecycle approach to compliance can help manufacturers achieve and maintain access to the Great Britain market while ensuring that medical devices remain safe, perform as intended and continue to meet applicable regulatory requirements.
How Can Patient Guard Help?
Navigating UK medical device regulations can be challenging, particularly as manufacturers need to manage both current requirements and an evolving regulatory framework.
Patient Guard provides regulatory and quality support to medical device manufacturers throughout the product lifecycle, from initial regulatory strategy and classification through to market access and ongoing post-market compliance.
Our UK medical device regulatory services include:
- UK Regulatory Strategy – helping manufacturers determine an appropriate route to the Great Britain market and understand the regulatory requirements applying to their devices.
- Medical Device Classification – assessing device classification and documenting the regulatory rationale.
- UK Responsible Person (UKRP) – acting as the UK Responsible Person for overseas manufacturers placing medical devices on the Great Britain market.
- MHRA Registration – supporting device registration and maintenance of regulatory information with the MHRA.
- UKCA Technical Documentation – preparing, reviewing and remediating Technical Documentation to support compliance with the UK MDR 2002.
- Clinical Evaluation – developing and maintaining Clinical Evaluation Plans and Clinical Evaluation Reports to support device safety and performance.
- Biological Evaluation – preparing biological evaluation strategies and documentation in accordance with applicable biocompatibility requirements.
- ISO 14971 Risk Management – developing and maintaining lifecycle Risk Management documentation.
- ISO 13485 Quality Management Systems – supporting the development, implementation and maintenance of medical device Quality Management Systems.
- Post-Market Surveillance – developing PMS Plans, PMS Reports, PSURs and systems for proactively monitoring device safety and performance.
- Vigilance Support – assisting manufacturers with incident assessment, regulatory reporting and Field Safety Corrective Actions where required.
- Regulatory Gap Assessments – reviewing existing documentation and compliance systems to identify gaps before market entry or regulatory assessment.
Support from Market Access to Post-Market Compliance
Patient Guard can support individual elements of the regulatory process or provide an integrated regulatory programme covering multiple stages of the device lifecycle.
For manufacturers based outside the UK, this can include acting as the UK Responsible Person while also supporting Technical Documentation review, MHRA registration and ongoing post-market obligations.
For UK manufacturers, support can range from initial classification and regulatory strategy through to Technical Documentation, Clinical Evaluation, Risk Management, Quality Management and Post-Market Surveillance.
Whether you are developing a new medical device, bringing an existing product to the Great Britain market or reviewing the compliance of an established portfolio, our regulatory team can help you identify the applicable requirements and develop a practical route forward.
Speak to a UK Medical Device Regulatory Expert
If you need support understanding the UK regulatory requirements for your medical device, contact Patient Guard to discuss your device, current regulatory position and intended route to the Great Britain market.
Frequently Asked Questions About UK Medical Device Regulations
Medical devices placed on the Great Britain market — England, Scotland and Wales — are primarily regulated under the Medical Devices Regulations 2002 (UK MDR 2002), as amended.
Different arrangements apply in Northern Ireland, where EU medical device legislation continues to play an important role. Manufacturers should therefore establish whether they intend to place their device on the Great Britain, Northern Ireland or both markets before determining their regulatory strategy.
Not necessarily. UKCA is the UK's domestic conformity marking for medical devices, but qualifying CE-marked medical devices can currently continue to be placed on the Great Britain market under transitional recognition arrangements.
The period for which CE marking is recognised depends on the type of device and the EU legislation under which it has been certified.
Under the current transitional arrangements, general medical devices compliant with the EU MDD or AIMDD may generally continue to be placed on the Great Britain market until the sooner of certificate expiry or 30 June 2028.
Devices compliant with the EU MDR and devices compliant with the EU IVDR can generally continue to be placed on the Great Britain market until 30 June 2030. Different arrangements apply to certain legacy IVDs.
Manufacturers should check the specific transitional provisions applying to their device and certification route.
Yes. Medical devices must be registered with the Medicines and Healthcare products Regulatory Agency (MHRA) before they are placed on the Great Britain market.
This includes general medical devices, IVDs, custom-made devices and systems or procedure packs.
Where the manufacturer is based outside the UK, registration is normally undertaken by its appointed UK Responsible Person.
A manufacturer based outside the UK that wishes to place medical devices on the Great Britain market must appoint a UK Responsible Person (UKRP).
The UKRP performs specified regulatory responsibilities on behalf of the manufacturer, including registering the manufacturer's devices with the MHRA and maintaining access to certain regulatory documentation.
No. Although the roles have similarities, they operate under different regulatory frameworks.
A UK Responsible Person represents an overseas manufacturer for the Great Britain market under the UK regulatory framework. An EU Authorised Representative represents a non-EU manufacturer under applicable European medical device legislation.
Manufacturers supplying devices in both Great Britain and the European Union may therefore require both a UK Responsible Person and an EU Authorised Representative.
No. Whether a UK Approved Body is required depends on the device classification, characteristics and conformity assessment route.
Many lower-risk Class I medical devices can be self-declared for UKCA marking. Higher-risk devices and certain Class I devices require independent conformity assessment by an appropriately designated UK Approved Body.
A UK Approved Body assesses devices for UKCA purposes and cannot issue CE certification under EU medical device legislation.
Manufacturers must maintain appropriate Technical Documentation demonstrating that their device complies with the applicable requirements of the UK MDR 2002.
Depending on the device, this can include the device description and intended purpose, design and manufacturing information, Essential Requirements evidence, Risk Management, Clinical Evaluation, verification and validation evidence, labelling, Instructions for Use and Post-Market Surveillance documentation.
Technical Documentation should be maintained and updated throughout the lifecycle of the device.
Strengthened Post-Market Surveillance requirements came into force in Great Britain on 16 June 2025.
Manufacturers must proactively collect and evaluate information about the safety, quality and performance of their devices after market entry. Requirements can include a PMS Plan, PMS Report or Periodic Safety Update Report, vigilance reporting, trend reporting and appropriate preventive or corrective actions.
Post-market information should also feed back into Risk Management, Clinical Evaluation, Technical Documentation and the manufacturer's Quality Management System.
Yes. The UK Government and MHRA are continuing to reform the regulatory framework for medical devices.
Post-Market Surveillance reforms are already in force, while further developments concern areas such as pre-market requirements, device identification and traceability, international recognition, software and AI medical devices and future routes to the Great Britain market.
Manufacturers should therefore monitor regulatory developments rather than assuming that today's requirements will remain unchanged.
For the 2026–2027 charging period, the MHRA annual medical device registration fee is £300 per applicable chargeable GMDN category.
In August 2026, the MHRA launched a public consultation proposing an increase to £511 per chargeable GMDN Level 2 category from 1 April 2027.
The £511 figure is currently a proposal and should not be treated as a confirmed future fee until the consultation process and subsequent government decision have been completed.
References
This guide is based on the following UK legislation, MHRA guidance and official regulatory resources relating to medical devices placed on the Great Britain market, including UKCA marking, CE recognition, MHRA registration, UK Responsible Person requirements, conformity assessment, clinical investigations, post-market surveillance and ongoing regulatory reform.
| Organisation | Reference | Why it's relevant |
|---|---|---|
| UK Government / MHRA | Regulating Medical Devices in the UK | Provides the core MHRA guidance for medical devices placed on the UK market, including the UK MDR 2002, UKCA marking, recognition of CE-marked devices, UK Responsible Person requirements, MHRA registration, Approved Bodies and the different arrangements applying in Great Britain and Northern Ireland. |
| UK Government | Medical Devices Regulations 2002 (SI 2002 No. 618) | Provides the primary legislative framework governing medical devices in Great Britain. The regulations establish requirements covering conformity assessment, classification, technical documentation, market access and ongoing regulatory responsibilities. |
| UK Government / MHRA | Register Medical Devices to Place on the Market | Sets out the requirements for registering medical devices with the MHRA before they are placed on the Great Britain market, including Device Online Registration System (DORS) requirements, manufacturer and UK Responsible Person responsibilities, GMDN information and registration fees. |
| UK Government / MHRA | Medical Devices: UK Approved Bodies | Provides the current list of organisations designated by the MHRA to undertake conformity assessment for UKCA marking and enables manufacturers to identify Approved Bodies whose designated scope covers their device and required conformity assessment activities. |
| UK Government / MHRA | Clinical Investigations in Great Britain | Provides official guidance on clinical investigations involving medical devices in Great Britain, including clinical evidence requirements, when MHRA notification may be required and the regulatory process for conducting an investigation. |
| UK Government / MHRA | Medical Devices: Post-Market Surveillance Requirements | Explains the strengthened post-market surveillance requirements that came into force in Great Britain on 16 June 2025, including PMS systems, PMS Plans, PMS Reports, PSURs, vigilance, trend reporting and corrective action. |
| UK Government / MHRA | Requirements of the Manufacturer's PMS System | Provides detailed guidance on establishing and maintaining a medical device post-market surveillance system, including proactive data collection, risk evaluation, PMS Plans, PMSRs, PSURs and the use of post-market information throughout the device lifecycle. |
| UK Government / MHRA | Designated Standards: Medical Devices | Provides the official list of standards designated by the UK Government for medical devices. These standards can support manufacturers in demonstrating conformity with applicable requirements, including standards relating to risk management and Quality Management Systems. |
| UK Government / MHRA | Implementation of the Future Regulation of Medical Devices | Provides information on the staged reform of the Great Britain medical device regulatory framework, including future pre-market requirements, international recognition, device identification, traceability and other planned regulatory changes. |
| UK Government / MHRA | MHRA Consultation on Statutory Fees 2026 | August 2026 public consultation covering proposed changes to MHRA statutory fees from 1 April 2027, including the proposed increase in the annual medical device registration charge from £300 to £511 per chargeable GMDN Level 2 category. |
UK medical device regulation continues to evolve. Manufacturers should consult the latest version of the UK Medical Devices Regulations 2002, current MHRA guidance and applicable designated standards when determining their regulatory strategy, conformity assessment route, registration requirements and ongoing post-market obligations.
Patient Guards Recent Posts
Cosmetic Product Safety Report (CPSR): A Complete Guide to UK Cosmetic Compliance
Before a cosmetic product can legally be placed on the UK market, manufacturers and Responsible Persons must demonstrate that it is safe for human use under normal or reasonably foreseeable conditions. The Cosmetic Product Safety Report (CPSR) is one of the most important regulatory documents required under the UK Cosmetics Regulation. This guide explains what a CPSR is, who can prepare one, what information it must contain, how it relates to the Product Information File (PIF) and how it supports legal cosmetic compliance.
IVDR PMPF Explained: A Complete Guide to Post-Market Performance Follow-up
Post-Market Performance Follow-up (PMPF) is a fundamental requirement under the EU In Vitro Diagnostic Regulation (IVDR), ensuring that manufacturers continually monitor the scientific validity, analytical performance and clinical performance of their in vitro diagnostic medical devices after CE marking. This guide explains IVDR PMPF requirements, PMPF Plans, PMPF Reports, Annex XIII expectations and how ongoing performance monitoring supports continued regulatory compliance throughout the device lifecycle.
IVDR Scientific Validity Explained: A Complete Guide for Manufacturers
Scientific Validity is the first pillar of IVDR Performance Evaluation and provides the scientific foundation demonstrating that an analyte or biomarker is associated with a specific clinical condition or physiological state. This guide explains Scientific Validity under Regulation (EU) 2017/746, including literature reviews, Scientific Validity Reports, Annex XIII requirements, evidence appraisal and how Scientific Validity supports successful CE marking.
Patient Guards Related Services
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
